Based on our analysis, the most likely targets for clinical approval in disease groups such as lymphoma and multiple myeloma are CD20, CD22 (or in combination with CD19), CD38, BAFFR, CD7, and CD5. The gene discussed is MS4A1; the disease is plasma cell myeloma.